HONEUR data partners Czech Republic - CLLEAR More... The Chronic lymphocytic leukemia (CLL) patients registry (CLLEAR) is a registry hosted by the Czech CLL Study Group and the Czech Leukemia...

Our 2023 HONEUR Summer Newsletter has been sent out. In this edition you can find an update on our ongoing and planned evidence-generation projects, a recap of our recent HONEUR Forum meeting in...

Thrilled to share the news of our upcoming fourth HONEUR Forum meeting in the picturesque city of Rome, Italy, on March 20-21, 2024! Calling upon our esteemed HONEUR Data Partners and potential...

In collaboration with our HONEUR Data partner Cancer Centre London, we published an abstract in Blood, entitled “An Honeur Framework for Generating Computer Understandable Cohort Definitions from...

We have shared our 2023 Winter HONEUR Newsletter. This edition features: 23 HONEUR data partners, with CHU Nice and Policlinico di Milano as our newest members: CHU de Nice The hematology...

We are delighted to introduce to you our 24th HONEUR data partner: ASST Ovest Milanese. The Hospital Healthcare company Ovest Milanese is a public organization which include 4 entities in an area...

ITEM CODE: RF-402052 | DATE OF PREPARATION: 12 FEBRUARY 2024

ITEM CODE: RF-402053 | DATE OF PREPARATION: 12 FEBRUARY 2024

Collage HONEUR Network Data Partners Data partners <strong>Data Partner</strong> List

ITEM CODE: CP-501468 | DATE OF PREPARATION: FEBRUARY 2025

What HONEUR Is About

Contact For general information: Giselle Lostaunau Costa, Project Lead glostaun@its.jnj.com For technical information: Michel Van Speybroeck, Data Science Director mvspeybr@its.jnj.com T: +32 479...

ITEM CODE: CP-502242 | DATE OF PREPARATION: FEBRUARY 2025

HONEUR’s cross-functional team EXECUTIVE SPONSOR Martin Price PhD Outcomes Research, Vice President Health Economics Outcomes Research and Reimbursement EMEA Executive Sponsor STEERING COMMITTEE...

Go to public sitemap

HONEUR Meeting

This Q&A has been prepared to answer questions about HONEUR and related topics.

Real World Data and Real World Evidence – What’s the difference? Real World Data (RWD) is health data, usually created by healthcare professionals and also by patients, as part of routine health...

HONEUR’s principles Do you want to know more about HONEUR’s network principles? Check it out here.

RWE in practice Sweden – Since 1998, Sweden's national Cataract Registry has collected nationwide data on postoperative endophthalmitis (PE), which, although rare, results in blindness in between...

Our Mission To create a secure, collaborative platform that enables participants across Europe to liberate the transformational potential of Real World Data. Our Vision We want to help create a...

Join the network To join the HONEUR network, only few prerequisites are needed. Basically, any registry, hospital, physician association or any scientific institute with a dataset on patients with...

What is HONEUR? HONEUR stands for Haematology Outcomes Network in Europe. Historically, the network of data centres across Europe has often been duplicative and uncoordinated, so the...

Real World Data is critically important RWD is very different from data gathered in clinical trials. In clinical trials, strict basic conditions are applied to allow for the best comparability...

Network Poster custom /documents/20126/0/Janssen+Honeur_VIEWPORT_piece.mp4/b4d9d321-0cb6-d701-7592-715e4bc3494f?t=1537260286947

Cookie Consent Settings

Not found the answer you are looking for? Please contact Lars Halvorsen and / or Peter Moorthamer for all your HONEUR related technical questions.

Terms of Use

COVID-19 Update

We are pleased to announce that the first site was contracted to the HONEUR network: Leicester Royal Infirmary is represented by Dr Mamta Garg, who is actively involved in research and functions as...

Our abstract “HONEUR (Haematology Outcomes Network in Europe) – A Federated Model to support Real World Data Research in Haematology” has been accepted at the Congress of the American Society of...

We are pleased to announce that we have signed the accession agreement to project HONEUR with Prof. Hajek from the Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. The RMG, which is...

Improving results for patients by realising the transformational potential of Real World Data BEERSE, BELGIUM, 11 April 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson have...

HONEUR’s new Interactive Patient Similarity Analysis and Visualisation Tool was accepted and published at EHA’s (European Haematology Association) 25th annual congress in June 2020. As every...

We're delighted to welcome six more data partners to join the HONEUR collaborative network of he Janssen Pharmaceutical Companies of Johnson & Johnson. HONEUR (Haematology Outcomes Network in...

Objective: enabling the use of distributed statistics across federated data models

News

CP-73766

What is HONEUR? Treating patients with haematological malignancies has progressed significantly in recent years, but extensive scientific research is still needed. Fortunately, there’s a huge...

Our mission With HONEUR, we have created a secure, collaborative platform that enables partnering data centres across Europe, including Janssen, to liberate the transformational potential of...